Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact

Breaking Down Silos. Connecting Expertise. Accelerating Patient Impact.

Biomarkers & CDx Program at Precision Medicine West

October 7-8, 2027
Hilton San Diego Bayfront, San Diego, CA, USA

The Biomarkers & CDx program covers the path from biomarker discovery and validation to companion diagnostics that reach patients. It is for translational and clinical biomarker leads, CDx developers, and regulatory and market access teams.

Session Themes

Which biomarkers will reach patients, and what will it take to get them approved and paid for? Sessions follow the biomarker from early evidence to clinical use, alongside the diagnostics, data and regulatory decisions it depends on. Session themes include:

Biomarkers in Translational & Clinical Development
How biomarkers are identified, validated and applied to guide patient stratification, treatment selection and personalized therapeutic strategies.

Tools & Technologies for Biomarker Analysis
How liquid biopsies, genomic tools and other emerging technologies are improving biomarker detection, analysis and interpretation.

Biomarkers for Clinical Trials & Personalized Patient Treatment
Using biomarkers to design better trials, stratify patients and predict treatment response.

Companion Diagnostics & Regulations
How companion diagnostics are developed, validated and regulated to support targeted therapies.

Featured Sessions

IVDR Regulations & Their Impact (panel) · AI-Enabled Clinical Trial Innovation: From Biomarker Data to Decisions (panel) · Proteomic Innovations to Drive Discovery · The Future of Liquid Biopsy: Emerging Technologies, Clinical Translation & Cross-Sector Collaboration

Biomarkers & CDx in San Diego

Building on a decade-long legacy of Biomarkers in San Diego, the Biomarkers & CDx program at Precision Medicine West brings established biotech and pharma expertise together with technology-led innovation from California's tech hubs, including the Bay Area and Silicon Valley.

Investment Forum Image 3

What's changed this year

Between October 2025 and October 2026, biomarker research advanced in five areas: AI-driven discovery, liquid biopsies for cancer detection and monitoring, multi-omics integration, non-invasive testing and stronger clinical validation. Blood-based biomarkers are opening the way to earlier diagnosis and ongoing monitoring. The challenge now is reproducibility, standardization and showing clinical benefit before routine use.

Who should attend

Translational and clinical biomarker leads

CDx developers 

Regulatory and market access teams 

Diagnostics companies 

Clinicians

Clinical trial experts 

Biomarker analysis teams

Biomarkers CDx Who Should Attend Image-2

Featured Speakers from Biomarkers & Companion Diagnostics US 2026

Antreas Hindoyan
Director of Precision Medicine,
Amgen
Bruce Wilcox
Chief Technology Officer,
PrognomiQ
Clemens Duerrschmid
Senior Manager, Field Applications,
Akoya Biosciences Inc
Colin McDowell
Senior Manager - Business Development,
Biodesix
Daniel Kim
Assistant Professor,
University of California, Santa Cruz
David Weingeist
Senior Director,
Johnson & Johnson Innovative Medicine
Dee Wu
Professor,
University of Oklahoma Health Sciences Center
Emre Gulturk
COO,
Imagene AI
Eric Peters
Vice President, Translational Medicine Scientific Operations, Diagnostics & Technology Innovation,
Genentech
Hebe Sun
Associate Director, Regulatory Affairs CDx,
Regeneron
Janell Cleveland
Senior Patent Agent,
MCCIP
Javier Perez
Senior Director, Precision Medicine Dx and Digital Pathology (DP/AI) Strategy - Oncology,
Regeneron
Show More Speakers
Hide Speakers
Jessica Perer
Associate Director, Translational Pathology,
Amgen
Kenneth Ramos
Executive Director,
Texas A&M University
Kirsty Maclean
Global Head, Research & Development,
Cerba Research
Komal Sane
IVD and Digital Health Regulatory Affairs,
Regeneron Pharmaceuticals
Lauren Leiman
Executive Director,
BLOODPAC
Lindsay Darling
Director, Clinical Laboratory & Diagnostic Delivery,
Regeneron Pharmaceuticals
Mini Manchanda
Senior Director, Precision Medicine: Clinical Biomarker and Diagnostics,
Kura Oncology
Minnie Sarwal
Professor,
University of California San Francisco
Nann Green
Vice President Business Developmennt,
Frontage Laboratories
Olivier Harismendy
Vice President,
Zentalis Pharmaceuticals
Pablo Tamayo
Professor, Division of Genomics and Precision Medicine,
UC San Diego
Patrick Reese
Vice President, Operations,
CellCarta
Petar Pop-Damkov
Director, Bioanalytical Strategy Lead, AstraZeneca,
CRUK AstraZeneca Antibody Alliance Laboratory
Rajashree Thakare
Associate Director IVD and Companion Diagnostic,
AbbVie
Sapna Yadavilli
Executive Director, Oncology Translational Medicine,
GSK
Tom Battersby
Executive Director, Biomarker Research,
Gilead Sciences
Veronica Ibarra Lopez
Scientist,
Genentech
Xiaojian Sun
Associate Director, Regulatory Affairs,
Regeneron
Xinru Mao
Senior Vice President, Pharma Biomarker & CDx Services and International Diagnostics Division. Burning Rock confirms the title directly.,
Burning Rock
Yasser Riazalhosseini
Head, Cancer Genomics,
McGill University
Yong Zeng
Professor,
University of Florida

2027 Program by numbers

25+

Speakers

31+

Sessions

31+

Hours of content

How it connects

Biomarkers & CDx focuses on clinical translation and treatment-linked diagnostic testing. It works hand in hand with the other three programs: new biomarker candidates from omics, pathology and data science need validated tests before they can inform clinical decisions. 

Frequently Asked Questions

Which biomarkers will reach patients, and what will it take?
The program puts patient impact at the center, with a dedicated track on Biomarkers for Clinical Trials & Personalized Patient Treatment. Sessions cover how to identify clinically actionable biomarkers, test their effectiveness and turn promising discoveries into clinical decisions.
How are IVDR regulations shaping precision medicine?
The Companion Diagnostics & Regulations track looks at how IVDR is shaping companion diagnostic development, clinical trial requirements and implementation, covering compliance, assay validation and NGS-based companion diagnostics. The panel IVDR Regulations & Their Impact discusses what comes next.
Which technologies will have the biggest impact on biomarker analysis?
Sessions span genomics, single-cell and spatial technologies, proteomics, mass spectrometry, flow cytometry and metabolomics, with dedicated discussions on proteomics and the future of liquid biopsy, and on how AI and machine learning strengthen discovery and patient stratification.
Who should attend the Biomarkers & CDx program?

Translational and clinical biomarker leads, CDx developers, regulatory and market access teams, diagnostics companies, clinicians, clinical trial experts and biomarker analysis teams.

When and where is the Biomarkers & CDx program at Precision Medicine West?
October 7-8, 2027 in San Diego, CA

Be part of the conversations shaping
the future of medicine.

October 7-8, 2027
Hilton San Diego Bayfront, San Diego, CA, USA

Spatial Multi-Omics 2026 Agenda at a Glance

DAY ONE 

Track 2: Emerging Multi-Omics Platforms and Applications: Genomics & Transcriptomics 
Track 3: Spatial Biology for Therapeutic Discovery & Development (Oncology & Immunology) 

DAY TWO 

Track 1: Emerging Multi-Omics Platforms and Applications: Proteomics, Epigenomics & Metabolomics 
Track 2: Spatial Biology for Therapeutic Discovery & Development
NGOUS Conference Brochure

Decision 1

Sentence describing Decision 1

Decision 2

Sentence describing Decision 2